Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 25, 2012

View Archived Issues

Itraconazole shows promise as an antiangiogenic and antitumor agent

New amatoxin conjugates patented by Heidelberg Pharma

Novel LRRK2 inhibitors prepared at Merck & Co.

Orchid Chemicals & Pharmaceuticals discloses new HDAC6 inhibitors

Japanese researchers synthesize new vitamin D receptor modulators

Novel anticancer agents presented by Kitasato Institute

New OGA inhibitors patented by Summit Corporation

Companies to develop self-injectable treprostinil

NX-1207 prostate cancer trial receives positive interim safety review

MBC Pharma and Maxwell Biotech enter joint venture in metastatic bone disease

FDA approves denosumab in new indication

MorphoSys reports phase Ib/IIa MOR-103 study results

Aradigm's inhaled liposomal ciprofloxacin shows promise in mouse models

First-in-human study of Opal-HIV-Gag(c) terminated

Eliglustat efficacy maintained for 4 years in patients with Gaucher's disease

Astex Pharmaceuticals discontinues amuvatinib development

Navidea Biopharmaceuticals receives NIH grant to develop RIGS agent

EMA committee recommends approval of new apixaban indication

ViroPharma and Halozyme provide update on development of Cinryze/rHuPH20

Sequestosome-1 identified as a biomarker of melanoma

CHMP recommends Constella in IBS-C

NewLink and Dendreon to collaborate on phase II study of combination treatment for prostate cancer

VIVUS anticipates CHMP opinion on Qsiva MAA

CHMP recommends expanded approval of Trajenta tablets

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 11, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...